Overview
- A peer‑reviewed analysis published Thursday, June 25, 2026 used TriNetX electronic health records from more than 170 institutions to compare two matched groups of over 430,000 adults with type 2 diabetes.
- The study found a roughly 48% higher likelihood of a new smell or taste diagnosis in GLP‑1 receptor agonist users, with an absolute incidence of 0.37% versus 0.22% in matched non‑users and raw counts of taste problems 769 versus 445 and smell problems 649 versus 316.
- Because the research is retrospective and based on EHR coding, the authors warn it cannot prove causation and may be affected by detection bias, coding differences, unmeasured confounders, and unclear timing or dose relationships.
- Clinicians say the sensory signal appears uncommon and should not generally outweigh GLP‑1 benefits for diabetes and weight control, but they advise patients and doctors to watch for changes that could affect eating, nutrition, safety, or quality of life.
- The paper calls for prospective, drug‑specific, and mechanistic studies to confirm the link, measure symptom severity and duration, and inform monitoring as GLP‑1 prescribing expands following recent guideline endorsements.